2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Yufeng Jane Tseng

Session 6 – Sharing Biotech Successes
Date: 23 July (Thursday) 10:40 – 12:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Prof. Yufeng Jane Tseng

Founder and scientific advisor
Yoda Pharmaceuticals Inc. 


Education:
2002 – Ph.D., Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL
1997 – B.S., Pharmacy, National Taiwan University, Taiwan
 
Current positions:
● Ministry of Science and Technology Science Park Application Review Committee
● Chairman, Asia SPARK Regional Committee
● Global SPARK executive committee
​● Director, SPARK Taiwan
● Research Fellow, National Applied Research Laboratories, Taiwan
● Associate Director, The Neurobiology and Cognitive Science Center, National Taiwan University
● Director, Drug Research Center, National Taiwan University
● Professor, Graduate Institute of Biomedical Electronics, and Bioinformatics, Department of Computer Science and Information Engineering, School of Pharmacy, National Taiwan University, Taiwan
● Program Chair, Drug Discovery Symposium, American Chemical Society National Meetings
● Principle Investigator, Metabolomics Core Laboratory, Genomic Center, National Taiwan University
 
Professional experiences:
2018 – 2018      Distinguished Research Fellow, Industrial Technology Research Institute, Taiwan
2017 – 2017      Advisor, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Taiwan
2011 – 2014      Steering Committee, Teach-Discover-Treat
2010 – 2015      Group Leader, Molecular modeling unit, Drug Research Center, National Taiwan University
2008 – 2014      Associate Professor, Graduate Institute of Biomedical Electronics, and Bioinformatics, Department of Computer Science and Information Engineering, School of Pharmacy, National Taiwan University, Taiwan
2006 – 2008      Assistant Professor, Institute of Biomedical Electronics, and Bioinformatics, Department of Computer Science and Information Engineering (joint position), School of Pharmacy (joint position since 2007), National Taiwan University, Taipei, Taiwan
2004 – 2006      Research Fellow, National Center of Biotechnology Information, National Institute of Health, Bethesda, MD, USA
1998 – 2006      Principal Molecular Modeling Software Developer, The Chem21 Group, Inc., Lake Forest, IL, USA
 
HONORS AND AWARDS
2020            NTU EE Alumni Innovation Award, Taiwan
2019            2019 Future Tech – Futuristic Breakthrough Technology Award, Taiwan
2019            National Bio-Innovation Award, Taiwan
2017            2017 Future Tech – Futuristic Breakthrough Technology Award, Taiwan
2017            Novartis Venture Fund Mentorship Grantee
2017            NTU EECS Academic Merit Award, Taiwan
2016            Novartis Venture Fund Mentorship Grantee (only two cases this year)
2016            National Bio-Innovation Award, Taiwan
2016            Ching Kang Foundation Young Investigator Award, Taiwan
2015            Drug Repurposing Innovation Award, TWi Pharmaceutical Foundation, Taiwan
2015            IBM Faculty Award, USA
2013             NTU EECS Outstanding Research Contribution Award, Taiwan
2013             American Chemical Society Chemluminary award, USA
2012             American Chemical Society Innovation Award, USA
2005- 2006       Intramural Training Award, National Center of Biotechnology Information, National Institute of Health, Bethesda, MD, USA
2001            Charles Bell Award for Computational Chemistry, University of Illinois at Chicago, Chicago, IL, USA


Sharing the Experience of Biotech Success
2020 Taiwan BIO Awards Recipients:

- Innovation of the Year
  NCE NMDA modulator-RS-D7

Yoda Pharmaceuticals Inc. is an innovative drug development company founded in 2019 in Taiwan. Partnering with international experts, Yoda utilizes state-of-the-art AI technology and big data to develop novel compounds in new drugs for unmet medical needs in neuropsychological diseases and neurological diseases.  Yoda is committed to bring innovations and transform lives of patients – may the force be with all of us.
 
RS-D7 is a novel NCE, with positive clinical data in treating schizophrenia and multiple systems atrophy. RS-D7 was jointly developed by professors and psychiatrists from NTU, NTU Hospital, NHRI, and NCTU in Taiwan, and licensed exclusively to Yoda Pharmaceuticals Inc. in 2019. Yoda is seeking investment to complete IND-enabling studies, IND filing, and clinical trials to advance the development and approval of RS-D7.
 
As an efficacious NCE to treat negative and cognitive symptoms of schizophrenia, RS-D7 differs from antipsychotics approved to date, which focus solely on treatment of positive and mood-related symptoms.  Clinical results from human studies indicate RS-D7 effectively improve patients’ verbal and visual memory and could potentially be used long-term, alone or in combination with other CNS drugs.
 
In addition, RS-D7’s proof-of-concept clinical trial resulted in positive therapeutic effects on alleviation of ataxia-related motor deficits in mice, pointing to potential of it becoming the first-in-class drug to treat multiple systems astrophy (MSA). MSA with cerebellar ataxia is a progressive brain disorder affecting movement and balance and disrupts the autonomic nervous system.  Treatment of MSA and ataxia is an unmet medical need as existing agents have shown no promising effect in relieving symptoms of ataxia and uncoordinated movements.